Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 10/20 | 0.60 |
| ▸ | BRD1 | O95696 | 8/20 | 0.60 |
| ▸ | BRPF3 | Q9ULD4 | 6/20 | 0.60 |
| ▸ | BRD4 | O60885 | 4/20 | 0.60 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.60 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.55 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.43 |
| ▸ | ATIC | P31939 | 3/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844273 | 0.87 | BRD4 (0.57) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6840912 | 0.86 | POLB (0.54) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6656125 | 0.86 | MEN1 (0.57) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6844284 | 0.84 | BRD1 (0.53) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6659457 | 0.84 | KMT2A (0.48) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6845454 | 0.84 | KMT2A (0.51) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6847813 | 0.84 | KEAP1 (0.60) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6846145 | 0.84 | ALDH1A1 (0.60) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6844486 | 0.82 | KMT2A (0.47) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL6665282 | 0.80 | LMNA (0.45) | BRPF1BRD1BRPF3BRD4BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | BRPF1 2930/4885BRD1 1341/4885BRPF3 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.